CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 201 enrolled
Drug / intervention
mometasone furoate nasal spray +1 moredrug
Likely dose
Mometasone furoate nasal spray 50 mcg/spray, intranasal administrationAI-extracted
Key inclusion· 3
  • ✓2-year history of seasonal allergic rhinitis
  • ✓Positive skin test response to a local seasonal allergen (current or within past year)
  • ✓Good health and free of unstable, clinically-significant disease other than allergic rhinitis that would interfere with study
Key exclusion· 11
  • ✕Pregnant or breastfeeding women
  • ✕Women of childbearing potential not using acceptable birth control
  • ✕Asthma requiring inhaled or systemic corticosteroids, cromolyn, or nedocromil
  • ✕Significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal or other significant medical illness

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03861559
NCT03861559Phase 3Completed
CompareCT.gov

Onset of Action of Mometasone Furoate (SCH 32088) Nasal Spray 50 mcg/Spray vs Placebo in Seasonal Allergic Rhinitis (Study No. C93-184).

Organon and Co·interventional·Posted Mar 4, 2019·Updated Feb 9, 2022

In Brief

A Phase 3 clinical trial evaluating mometasone furoate nasal spray and placebo nasal spray for Rhinitis, Allergic, Seasonal. Completed, enrolled 201 participants.

Detailed Summary

This study investigated the onset of symptom relief following initiation of treatment with mometasone furoate (MK-0887/SCH 032088) 200 mcg administered once daily compared with placebo for 14 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Seasonal
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 4, 2019
Enrollment StartMar 30, 1994
Primary CompletionJun 27, 1994
Study CompletionJul 7, 1994
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.3 years ago

Interventions

mometasone furoate nasal spraydrug

intranasal administration

placebo nasal spraydrug

intranasal administration